Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 61Neoplasm Metastasis 7Neoplasms 5Endometrial Neoplasms 4Neoplasms by Site 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Diseases 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Ovarian Neoplasms 2Neuroblastoma 2Melanoma 2Hereditary Sensory and Autonomic Neuropathies 2Glioma 2Glioblastoma 2Carcinoma, Ovarian Epithelial 2Anatomic Stage II Breast Cancer AJCC v8 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Sarcoma 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Meningioma 1Medulloblastoma 1

Interventions

Temozolomide 7Radiotherapy 4Cyclophosphamide 3TIC10 compound 2Specimen Handling 2Irinotecan 2Granulocyte-Macrophage Colony-Stimulating Factor 2Everolimus 2Etoposide 2Diphtheria-Tetanus Vaccine 2tovorafenib 1spartalizumab 1ribociclib 1pembrolizumab 1olutasidenib 1lutetium Lu 177 dotatate 1lorlatinib 1larotrectinib 1gallium maltolate 1fimepinostat 1etoposide phosphate 1dostarlimab 1dipinacoline glutamate 1dinutuximab 1balstilimab 1antineoplaston AS 2-1 1antineoplaston A10 1abemaciclib 1Vaccines 1Topotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diffuse Intrinsic Pontine Glioma × ribociclib × 1 year × Clear all
NCT05843253 2026-05-29

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Nationwide Children's Hospital

Phase 2 Recruiting
120 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡